Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants

Lupus anticoagulants (LA) are one laboratory criterion for classification of antiphospholipid syndrome, with presence of vascular thrombosis and/or pregnancy/fetal morbidity being clinical criteria. The presence of LA is detected (or excluded) by laboratory testing, with the activated partial thromb...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Research and practice in thrombosis and haemostasis Jg. 6; H. 2; S. e12676 - n/a
Hauptverfasser: Favaloro, Emmanuel J., Pasalic, Leonardo
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States Elsevier Inc 01.02.2022
Elsevier Limited
John Wiley and Sons Inc
Elsevier
Schlagworte:
Anticoagulants
apixaban
clinical laboratory techniques
dabigatran
direct oral anticoagulants
DOACs
Hematology
Laboratories
Lupus
lupus anticoagulant
Molecular weight
Patients
Reagents
Review
rivaroxaban
Thrombosis
direct oral anticoagulants
DOACs
dabigatran
rivaroxaban
clinical laboratory techniques
lupus anticoagulant
apixaban
ISSN:2475-0379, 2475-0379
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Lupus anticoagulants (LA) are one laboratory criterion for classification of antiphospholipid syndrome, with presence of vascular thrombosis and/or pregnancy/fetal morbidity being clinical criteria. The presence of LA is detected (or excluded) by laboratory testing, with the activated partial thromboplastin time and dilute Russell's viper venom time the most commonly used tests. Given the association of thrombosis with LA, it is no surprise that anticoagulants are used to treat or manage such patients. To review and discuss interferences from anticoagulants on LA testing, and strategies to mitigate these. This narrative review assessed interference from commonly used anticoagulants, focusing on LA testing while on direct oral anticoagulants (DOACs), including use of DOAC neutralizers. The classical anticoagulants comprise vitamin K antagonists such as warfarin, and heparins, predominantly unfractionated heparin and low molecular weight heparin (LMWH). DOACs have emerged with favorable efficacy and safety. These comprise two classes: direct anti‐thrombin (anti‐IIa; dabigatran) or direct anti‐Xa (rivaroxaban, apixaban, edoxaban) agents. All anticoagulants affect clotting assays, although there are differences in effects according to anticoagulant and assay. Nevertheless, because of such interferences, anticoagulants can lead to false‐negative or false‐positive LA findings. Several strategies can mitigate such interferences, including avoidance of testing while patients are on such anticoagulants, temporarily switching to an anticoagulant (i.e., LMWH) with less assay interference, testing for LA at nadir levels of anticoagulants, and/or use of anticoagulant neutralizers. Whilst the best approach is to avoid LA testing on patients taking anticoagulants; if unavoidable, testing may be facilitated by various mitigating strategies.
Bibliographie:Handling Editor: Pantep Angchaisuksiri
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2475-0379
2475-0379
DOI:10.1002/rth2.12676